scorecardresearch
Add as a preferred source on Google
Saturday, November 15, 2025
TopicSickle cell

Topic: sickle cell

‘Genetic scissors’ — India using same tech to find sickle cell cure as gene therapy approved by US FDA

FDA-approved Casgevy & Lyfgenia made from patients’ blood stem cells which are modified and given back as single-dose infusion. India ‘in preclinical stage’ of trial of similar therapy.

Cure for sickle cell disease on the horizon? US drug regulator is reviewing 2 new gene therapies

FDA is scheduled to review gene therapies from two American companies — Vertex Pharmaceuticals & Bluebird Bio Inc. If approved, therapies could mean a breakthrough for curing SCD.

Anaemia in India has a caste angle. That’s where new Modi govt scheme can help

India has the highest prevalence of sickle cell anaemia in South Asia. The new National Sickle Cell Anaemia Elimination Program can be a trendsetter.

Sickle-cell anemia cards for all tribals below 40, screening to start from Chhattisgarh

Under the programme, all 7 crore tribals will get the identity cards which will tell if they are positive or carriers. The cards are to be matched before a marriage.

On Camera

Why Tejashwi Yadav failed—Bihar changed, RJD didn’t

RJD, once a prominent representative of Mandal politics, now finds itself in a political era where welfare, good governance, and new aspirations are overshadowing old caste equations.

As govt starts rolling back Quality Control Orders, a look at adverse impact they had, mainly on MSMEs

Between 2016 and 2025, around 700 QCOs were issued by the government. Now, it has withdrawn 69 of them.

Drone manufacturer ideaForge wins orders worth over Rs 100 crore from Army

ideaForge has formed a joint venture to manufacture and market UAVs in the US. Its Q6 UAV is now included in NATO and allied procurement systems.

INDIA has a Congress-sized hole. And the fix begins with a little humility

Without a Congress revival, there can be no challenge to the BJP pan-nationally. Modi’s party is growing, and almost entirely at the cost of the Congress.